Genotyping human UDP-glucuronsyltransferase 2B15 (UGT2B15) genes

Abstract

Genetic polymorphisms are identified in the human STP2 gene that alter STP2-dependent drug metabolism. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for STP2 substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and in vitro models for drug metabolism.

What is claimed is:  
     
         1 . An isolated nucleic acid molecule comprising a STP2 sequence polymorphism, as part of other than a naturally occurring chromosome.  
     
     
         2 . A nucleic acid probe for detection of STP2 locus polymorphisms, comprising a polymorphic sequence listed in Table 4.  
     
     
         3 . A nucleic acid probe according to  claim 2 , wherein said probe is conjugated to a detectable marker.  
     
     
         4 . An array of oligonucleotides comprising: 
 two or more probes for detection of STP2 locus polymorphisms, said probes comprising at least one form of a polymorphic sequence listed in Table 4.    
     
     
         5 . A method for detecting in an individual a polymorphism in STP2 metabolism of a substrate, the method comprising: 
 analyzing the genome of said individual for the presence of at least one STP2 polymorphism listed in Table 4; wherein the presence of said predisposing polymorphism is indicative of an alteration in STP2 expression or activity.    
     
     
         6 . A method according to  claim 5 , wherein said analyzing step comprises detection of specific binding between the genomic DNA of said individual with an array of oligonucleotides comprising: 
 two or more probes for detection of STP2 locus polymorphisms, said probes comprising at least one form of a polymorphic sequence listed in Table 4.    
     
     
         7 . A method according to  claim 5 , wherein said alteration in STP2 expression is tissue specific.  
     
     
         8 . A method according to  claim 5 , wherein said alteration in STP2 expression is in response to a STP2 modifier.  
     
     
         9 . A method according to  claim 8 , wherein said modifier induces STP2 expression.  
     
     
         10 . A method according to  claim 8 , wherein said modifier inhibits STP2 expression.